|
KMID : 0370220200640040243
|
|
Yakhak Hoeji
2020 Volume.64 No. 4 p.243 ~ p.249
|
|
|
Trends in the Development of Castration-resistant Prostate Cancer Treatment
|
|
Kim Ji-Won
Lee Jun-Nyung
Ha Yun-Sok
Kwon Tae-Gyun
Lee Sang-Kyu
|
|
|
Abstract
|
|
|
|
Prostate cancer is one of the most common male cancer. It tends to be known as “mild cancer” due to its highfive-year survival rate. However, some patients develop castration-resistant prostate cancer (CRPC) during androgendeprivation therapy (ADT) treatment, with high metastasis and poor prognosis. In addition to conventional ADT treatments,specific treatments are implemented for CRPC. There are four second-generation anti-androgen drugs, taxane chemotherapy,and immunotherapy using vaccines and monoclonal antibodies. This review paper outlines the mechanism of prostatecancer leading to CRPC and reviews the standard treatment of CRPC. It also summarized the trends of anticancer drugsunder clinical trials to obtain CRPC as an additional indication.
|
|
|
KEYWORD
|
|
|
castration-resistant prostate cancer, anti-androgens, prostate cancer, chemotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|